VolitionRx Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
VNRX Community Narratives
Early Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains
Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential
Epigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care
Blood Diagnostics Partnerships And NETs Platform Will Drive Long Term Upside Potential
View narrativeEarly Cancer Detection Headwinds Will Persist Yet Long-Term Liquid Biopsy Potential Remains
View narrativeEpigenetic Diagnostics And NETs Platform Will Reshape Long Term Prospects In Cancer And Autoimmune Care
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
VNRX: Sepsis And Lung Cancer Data Will Drive Repricing Potential
VNRX: Turnaround Will Rely On Advancing Liquid Biopsy And Sepsis Testing
VNRX: New Diagnostics Progress And Reduced Share Authorization Will Drive Repricing
Snowflake Analysis
VolitionRx Limited Key Details
- -1.84
- 100.00%
- -1,061.82%
- -31.9%
About VNRX
- Founded
- n/a
- Employees
- 57
- CEO
- Website
View website
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.